Compass Therapeutics rises as Wainwright cheers co's lead asset, cash position

Compass Therapeutics

23/05/2022 13:54

** Shares of cancer-focused drugmaker  CMPX.O  rise 5.4% to
$2.73 premarket after H.C. Wainwright starts with "buy" 
    ** Assigns PT of $12; median PT is $10 as per Refinitiv data
    ** Brokerage notes co has not delivered any disappointments
to date
    ** Says CMPX's capital raises have placed it in a
"significant" positive position, with resources to the end of
2024 in addition to being debt free
    ** Encouraged by progress in co's lead asset, CTX-009 - an
antibody that prevents tumor activity; highlights flexibility in
co's antibody tech platform which could aid long-term product
pipeline 
    ** Stock down 18% YTD, as of last close 
    

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))